No Data
Increased support for innovative drugs, the collective rise of the innovative drug sector, sino biopharm (01177) rose 4.5%.
Jingu Finance News | The innovative drug sector as a whole is on the rise, with Lai Kai Medicine (02105) up 6.07%, Sino Biopharm (01177) up 4.5%, Genscript Bio (01548) up 4.07%, Hutchmed (China) (00013) up 2.68%, and Innovent Bio (01801) up 2.1%. The State Council Information Office held a series of themed press conferences on 'Promoting High-Quality Development', and Li Li, Director of the National Medical Products Administration, stated at the conference the increased support for pharmaceutical R&D innovation. This includes the evaluation and approval, inspection and verification of innovative drugs and medical instruments that are key to the country's support.
Innovent Biologics Could Turn Profitable From 2025 -- Market Talk
Innovent Biologics Started at Add by China Galaxy International >1801.HK
The biopharmaceutical sector is showing strong momentum. Kelunbotai Bio (06990) rose 6.6%, and institutions pointed out that innovative drug companies are gradually approaching the breakeven point in terms of profit and loss.
Jinwu Financial News | The biopharmaceutical sector has shown strong performance, with Kexingbo Tai Bio (06990) up 6.6%, Kanno (02162) up 5.9%, Hutchmed (China) (00013) up 4.42%, and Innovent Bio (01801) up 3.81%. In terms of news, Zhongyin International Securities stated that the revenue growth of the innovative drugs sector is strong. Among the sectors, the best-performing sector is innovative drugs (Biotech), with an average revenue growth of 25.3%, mainly due to the positive medical insurance payment environment for innovative drugs and the authorized revenue obtained by some innovative drug companies through product overseas licensing.
Express News | Head-to-Head Superiority Over Dulaglutide: Innovent's Phase 3 Clinical Trial Dreams-2 of Mazdutide in Chinese Patients With Type 2 Diabetes Were Orally Presented at Easd 2024
Head-to-head superiority to high-dose liraglutide, the phase III clinical study results of marserlin peptide for diabetes, DREAMS-2, were orally reported at EASD.
San Francisco, USA, and Suzhou, China, September 12, 2024 / PRNewswire / - Innovent Biologics Group (Hong Kong Stock Exchange: 01801), a biopharmaceutical company dedicated to the research, development, production, and sales of innovative drugs in major disease areas such as oncology, autoimmune, metabolism, cardiovascular, and ophthalmology, announced today that Marstedinide (research code: IBI362), a dual GLP-1R/GCGR agonist, for the treatment of type 2 diabetes, has initiated its Phase III clinical trial (DREAMS-2) in Chinese subjects.
No Data
No Data
